Search

Ahmad K Safavy

from Vestavia, AL
Age ~73
Get Report
Also known as:
Ahmad N Safavy, Ahamd Safavy, Kamellia Safavy, Shirin Safavy, Ahmad Y
Phone and address:
4456 Galen Cv, Birmingham, AL 35242
(205) 967-4639
Related to:
Maranda R Kalousek, 24Clarence Rager, 84Anthony Rager, 55Cynthia Brug, 67Catherine Jenks, 38
Connected to:
Elaine R Safavynia, 70Stephanie G Safchuck, 41Aiman Safdar, 40Gina A Safdar, 71Haroon Safdar, 35Javed Safdar, 56Maryam Safdar, 27Mohammad Safdar, 73Mohammed Safdar, 70Mehrdad Safdari, 61

Ahmad Safavy Phones & Addresses

  • 4456 Galen Cv, Birmingham, AL 35242 (205) 967-4639
  • 332 Crowne Woods Dr, Birmingham, AL 35244
  • 1366 Anglewood Dr, Vestavia Hills, AL 35216
  • Vestavia, AL

Resumes

Resumes

Ahmad Safavy Photo 1

Editor

View page
Location:
Birmingham, AL
Industry:
Biotechnology
Work:
Editorial Board Journal of Analytical and Pharmaceutical Research
Editor
Linktoconsult
President
Chemical and Biotech Industries
Consultant
The University of Alabama at Birmingham Jan 1991 - Apr 2010
Associate Professor and Scientist
Education:
University of Alabama 1981 - 1986
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry The University of Alabama 1981 - 1986
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry
Skills:
Chromatography
Spectroscopy
Organic Chemistry
Biochemistry
Cell
Purification
Ahmad Safavy Photo 2

Ahmad Safavy

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ahmad Safavy
incorporator
Linktoconsult, Inc
PROFESSIONAL CONSULTANTS SERVICES
Birmingham, AL 35242
Ahmad Safavy
Incorporator
Biolinx, Inc
Resale Of Small Quanity Chemicals
Birmingham, AL

Publications

Us Patents

Multidrug Multiligand Conjugates For Targeted Drug Delivery

View page
US Patent:
7311892, Dec 25, 2007
Filed:
Oct 28, 2002
Appl. No.:
10/281840
Inventors:
Ahmad Safavy - Vestavia Hills AL, US
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
A61K 39/00
A61K 39/385
A61K 47/08
A61K 51/08
C07K 17/18
US Classification:
424 169, 4241691, 4241811, 4241931, 4241941, 4241951, 530329, 5303911, 514 15, 514 16
Abstract:
Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a scaffold binding element. The MDML conjugate allows for more efficient delivery of therapeutic agents to the cells resulting in enhanced therapeutic efficiency. A model MDL conjugate is disclosed as well as method for the synthesis of the model conjugate.

Multidrug Multiligand Conjugates For Targeted Drug Delivery

View page
US Patent:
7807134, Oct 5, 2010
Filed:
Dec 19, 2007
Appl. No.:
11/959947
Inventors:
Ahmad Safavy - Vestavia Hills AL, US
International Classification:
A61K 51/06
A61K 38/08
A61K 38/04
A61K 39/00
A61K 39/385
US Classification:
424 169, 4241691, 4241811, 4241931, 4241941, 42419511, 514 15, 514 16, 530329, 5303911
Abstract:
Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a scaffold binding element. The MDML conjugate allows for more efficient delivery of therapeutic agents to the cells resulting in enhanced therapeutic efficiency. A model MDL conjugate is disclosed as well as method for the synthesis of the model conjugate.

Single-Drug Multi-Ligand Conjugates For Targeted Drug Delivery

View page
US Patent:
20100166654, Jul 1, 2010
Filed:
Dec 2, 2005
Appl. No.:
11/792329
Inventors:
Ahmad Safavy - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
A61K 47/48
C07K 7/06
C07D 305/14
A61K 51/08
A61K 49/14
A61P 37/06
A61P 29/00
A61P 35/00
A61P 9/10
A61P 31/00
C12N 9/96
US Classification:
424 169, 530328, 530329, 549510, 514 16, 424 934, 435188, 977774
Abstract:
An adhesive is provided containing at least one synthetic polymer with receptor sites that enable the selective capture or release of a target molecule. A polymer is synthesized by polymerizing and cross-linking a functional monomer or functional copolymers in the presence of a target or template molecule allowing for reversible interactions between the polymer and the target molecule. The target molecule may be extracted from the polymer creating receptor sites complimentary to the target molecule. Alternatively, the target molecule may remain in the polymer network and be controllably released. The molecularly imprinted polymer is formulated into an adhesive. The adhesive can be used as a component in an in-vitro diagnostic device to release template molecules or to capture target molecules in vacated receptor sites in the synthetic polymer.

Water Soluble Curcumin-Based Compounds

View page
US Patent:
20100316631, Dec 16, 2010
Filed:
Oct 19, 2007
Appl. No.:
12/446375
Inventors:
Ahmad Safavy - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
A61K 39/395
C07C 57/42
C07C 49/255
C07D 317/54
C07C 49/172
C07H 15/203
C07K 2/00
C07C 229/34
C07K 16/00
A61K 31/36
A61K 31/192
A61K 31/197
A61K 31/12
A61K 31/7034
A61P 35/00
A61P 29/00
C08G 73/06
US Classification:
4241331, 562496, 568325, 549446, 568328, 568308, 568331, 536 41, 530300, 562452, 5303873, 514464, 514568, 514567, 514682, 514685, 514679, 514678, 514 35, 525417
Abstract:
The present disclosure describes the design and synthesis of a novel class of water soluble curcumin-based compounds. These water soluble curcumin-based compounds are shown to provide superior cell killing activity and exhibit increased and cell internalization solubility in aqueous solutions as compared to the free (unconjugated) curcumin. The present disclosure provides compositions for the treatment or prevention of a variety of disease states or conditions, such as but not limited to, cancer, other cell hyperproliferative disorders and chronic inflammatory conditions, said compositions comprising a water soluble curcumin-based compound.

Bis-Aromatic Anticancer Agents

View page
US Patent:
20110054037, Mar 3, 2011
Filed:
Apr 6, 2009
Appl. No.:
12/936608
Inventors:
Ahmad Safavy - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
A61K 31/135
A61K 31/095
A61K 31/075
C12N 5/00
C07C 381/00
A61P 35/00
US Classification:
514649, 514712, 514717, 435375, 568 47
Abstract:
Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described.

Heterofunctional Segment-Poly (Ethylene Glycol) Polymers As Delivery Vehicles

View page
US Patent:
20110293515, Dec 1, 2011
Filed:
Jan 12, 2010
Appl. No.:
13/144440
Inventors:
Ahmad Safavy - Birmingham AL, US
James A. Bonner - Birmingham AL, US
Donald J. Buchsbaum - Alabaster AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
A61K 51/06
A61P 35/00
A61K 49/00
C08G 69/48
A61K 47/48
US Classification:
424 165, 525436, 525 541, 525 542, 424 7817, 424 91
Abstract:
Heterofunctional segment-poly(ethylene glycol) polymers, conjugates of these molecules with therapeutic and/or imaging agents, and methods for their use are disclosed. The heterofunctional segment-poly(ethylene glycol) polymers are useful as drug delivery conjugates, i.e., the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to therapeutic agents (e.g., pharmaceutically active agents) and serve as delivery vehicles for the therapeutic agents. The heterofunctional segment-poly(ethylene glycol) polymers are also useful as imaging agent conjugates, i.e. the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to imaging agents (e.g., tracers, imaging atoms, and imaging molecules) and serve as delivery vehicles for the imaging agents. Also disclosed are methods for treating a subject by administering to the subject an effective amount of the polymers conjugated to a therapeutic agent, an imaging agent, or a mixture thereof.

Hydroxamic Acid-Based Bifunctional Chelating Compounds

View page
US Patent:
57568251, May 26, 1998
Filed:
Apr 16, 1993
Appl. No.:
8/048869
Inventors:
Ahmad Safavy - Birmingham AL
Donald J. Buchsbaum - Birmingham AL
International Classification:
C07C22900
C07C23900
US Classification:
560169
Abstract:
The present disclosure details the preparation of hydroxamic-acid based bifunctional chelators and their use in conjugating metal ions to proteins and nucleic acids for tumor or tissue imaging or therapy purposes. Some preferred aspects of the disclosure involve the preparation of trisuccin, chemical name N-�tris(2-N- benzyloxyaminocarbonylethyl)! methylsuccinamic acid, which is a hydroxamic acid/succinate based structure that is particularly useful for binding radionuclides such as. sup. 99m Tc,. sup. 186 Re and. sup. 67 Cu.

Taxane Derivatives For Targeted Therapy Of Cancer

View page
US Patent:
61912905, Feb 20, 2001
Filed:
Feb 23, 2000
Appl. No.:
9/510896
Inventors:
Ahmad Safavy - Birmingham AL
Assignee:
UAB Research Foundation - Birmingham AL
International Classification:
C07D30514
A61K 31337
US Classification:
549510
Abstract:
The present invention describes for the first time the design and synthesis of a soluble tumor-directed paclitaxel prodrug which may establish a new mode of utilization of the taxane class of anticancer agents in cancer therapy.
Control profile
Ahmad K Safavy from Vestavia, AL, age ~73 Get Report